Trevi Therapeutics enters critical inflection point as clinical validation supports pipeline advancement in underserved pulmonary segment

Trevi Therapeutics, Inc. has announced that results from its Phase 2b CORAL trial evaluating oral nalbuphine extended-release (nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) patients have been published in the Journal of the American Medical Association (JAMA). The peer-reviewed data highlight a statistically significant reduction in 24-hour objective cough frequency across all tested doses and reinforce early symptom improvement from Week 2 onward, a milestone that marks a potential breakthrough in a segment with no FDA-approved therapies.

Why JAMA publication signals more than trial validation for Trevi’s cough program

Although the core findings of the CORAL trial were previously known, the publication of data in a high-impact medical journal like JAMA serves as more than academic validation. For a development-stage biopharmaceutical company like Trevi Therapeutics, third-party vetting of clinical rigor represents a crucial trust-building mechanism with regulators, potential partners, and institutional investors.

The consistency between objective monitoring and patient-reported outcomes also strengthens the case for nalbuphine ER’s therapeutic value. In chronic cough, where subjective experience and measurable outcomes often diverge, dual confirmation reduces the clinical ambiguity that can hinder regulatory and payer confidence. This alignment may help Trevi craft a compelling label narrative should the program move into a Phase 3 pivotal setting.

Importantly, over 60 percent of patients treated with nalbuphine ER achieved a 50 percent or greater reduction in cough frequency by Week 6, suggesting clinically meaningful benefit. Industry analysts tracking the sector note that this magnitude of reduction approaches the thresholds viewed as relevant by pulmonologists and respiratory trialists, especially in the absence of approved options.

What the CORAL trial reveals about dose-response and tolerability in pulmonary populations

The CORAL study assessed three dose levels of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) over a six-week period in 165 patients with IPF-related chronic cough. The inclusion of multiple dose arms and a clearly defined modified intent-to-treat population signals an effort to de-risk both efficacy and safety parameters prior to late-stage progression.

The results point to statistically significant efficacy across all doses, but also suggest that tolerability did not deteriorate at higher exposure levels. Discontinuation rates were balanced between active treatment and placebo groups, and the most commonly reported adverse events—nausea, fatigue, somnolence—are consistent with known class effects. Clinicians watching the trial landscape believe this safety profile compares favorably with other centrally acting neuromodulators, which have historically faced challenges in respiratory populations due to sedation or GI toxicity.

The safety data also reinforces the suitability of nalbuphine ER in a fragile, comorbidity-laden patient population such as those with IPF. Given the limited pulmonary reserve of these patients, any candidate showing therapeutic activity without exacerbating respiratory compromise gains additional strategic value.

Why IPF chronic cough is emerging as a high-priority subsegment for clinical innovation

Idiopathic pulmonary fibrosis, while rare, presents a disproportionately high symptom burden driven in large part by chronic cough. Patients with IPF may cough over 1,000 times per day, and clinicians underscore that the impact extends beyond discomfort—it correlates with faster disease progression, increased hospitalizations, and reduced survival.

Approximately 100,000 to 150,000 people in the United States are estimated to have IPF, with up to two-thirds experiencing chronic cough refractory to conventional treatment. Yet no drug is currently approved by the U.S. Food and Drug Administration for this indication. The lack of historical success has turned chronic cough in IPF into a high-risk, high-reward opportunity, attracting players like Trevi Therapeutics willing to pursue nuanced endpoints and invest in objective monitoring tools.

Industry observers believe that Trevi’s focus on IPF-related cough, rather than broader, etiologically diverse chronic cough populations, may give it an advantage in trial design specificity and regulatory positioning. Narrower indication targeting can improve effect size detection and may allow for fast-track or breakthrough therapy designations in the future.

What nalbuphine ER’s mechanism reveals about potential expansion into adjacent respiratory indications

Nalbuphine ER functions as a kappa opioid receptor agonist and a mu opioid receptor antagonist (KAMA), acting both centrally and peripherally on the cough reflex arc. This dual modulation strategy positions the candidate differently from P2X3 antagonists, which have had mixed results in recent chronic cough trials, particularly in broader, non-IPF populations.

The mechanistic distinction opens the door to multiple respiratory indications where cough is a disabling symptom but lacks therapeutic attention. Trevi is already exploring nalbuphine ER in non-IPF interstitial lung disease and refractory chronic cough, and clinicians believe the pathway could extend further into COPD-related chronic cough or post-infectious cough syndromes, if efficacy and safety trends hold.

Pulmonologists consulted about the trial results note that mechanism-based stratification will become increasingly important as the cough therapeutics field matures. A differentiated mechanism such as KAMA modulation could play well in markets fatigued by the underperformance of P2X3 programs, particularly in light of taste-related side effects and inconsistent efficacy seen with agents like gefapixant.

What regulatory and commercial hurdles remain before nalbuphine ER becomes a viable therapeutic option

Despite encouraging Phase 2b data, nalbuphine ER remains an investigational therapy with no formal regulatory filings to date. For approval in the United States, Trevi will likely need to initiate a Phase 3 trial with rigorous endpoint harmonization and long-term safety monitoring, particularly given the opioid receptor activity profile.

While nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency, regulatory scrutiny around any opioid-modulating compound remains heightened. Industry experts caution that labeling discussions, post-marketing commitments, and abuse potential assessments could introduce delays even if efficacy is clearly demonstrated in future trials.

Commercially, scale-up presents a challenge. Nalbuphine is a well-known compound, historically used as an injectable analgesic, but Trevi’s oral ER formulation represents a novel application. Ensuring reliable, scalable production of the ER format, combined with the unique dose titration needs seen in CORAL, may require dedicated formulation and supply chain partnerships.

Reimbursement could also be complex. As nalbuphine ER may sit between symptom relief and disease-modifying classification, payers will expect a clear health-economic rationale. Demonstrating that cough reduction meaningfully reduces hospitalization rates or improves patient-reported quality-of-life scores will be essential to justify pricing in a constrained specialty care market.

What signals stakeholders should watch next in the IPF cough treatment landscape

Stakeholders will likely focus on three near-term developments. First, any signal from Trevi Therapeutics regarding a Phase 3 trial initiation or regulatory engagement will be closely watched. A protocol aligned with recent FDA guidance on chronic cough endpoints could de-risk the submission pathway significantly.

Second, head-to-head or cross-trial comparisons with other emerging agents in chronic cough, particularly those targeting P2X3 and TRPV1 pathways, will begin to shape the competitive narrative. Nalbuphine ER’s performance in these contexts will influence its commercial positioning.

Finally, the publication in JAMA itself may have an amplifying effect beyond scientific circles. Peer-reviewed credibility can influence trial site recruitment, institutional investor confidence, and even potential licensing or partnership conversations, especially as respiratory portfolios become more strategic for mid-sized biotech firms and specialty pharma players.

  chronic cough, CORAL trial, cough therapeutics, Haduvio, idiopathic pulmonary fibrosis, IPF, JAMA, nalbuphine ER, refractory chronic cough, Trevi Therapeutics